Loading...
Loading...
An exploration of senolytic therapy — from the Mayo Clinic's groundbreaking fisetin research to the first human clinical trials targeting cellular senescence.
As we age, damaged cells that should die instead enter a state called senescence — they stop dividing but refuse to die. These "zombie cells" accumulate throughout the body, secreting a toxic cocktail of inflammatory molecules called the SASP (Senescence-Associated Secretory Phenotype).
Senescent cells make up only a small fraction of total cells (10-15% by age 80), but their inflammatory secretions:
Senolytics are compounds that selectively destroy senescent cells while leaving healthy cells intact. The concept was pioneered by James Kirkland's team at the Mayo Clinic.
Dasatinib + Quercetin (D+Q): The first senolytic combination tested in humans. Dasatinib (a leukemia drug) targets senescent fat cell progenitors; quercetin targets senescent endothelial cells.
Fisetin: A strawberry-derived flavonoid identified by the Mayo Clinic as the most potent natural senolytic. Extended remaining lifespan by 10% in aged mice.
Navitoclax (ABT-263): A potent pharmaceutical senolytic but with significant side effects (thrombocytopenia).
The first human senolytic trial (Hickson et al., 2019) showed D+Q improved physical function in patients with idiopathic pulmonary fibrosis after just 3 doses over 3 weeks. Subsequent trials have shown reduced senescent cell burden in diabetic kidney disease patients.
Unlike daily supplements, senolytics work best in intermittent high-dose bursts — typically 2-3 consecutive days per month. This "hit-and-run" approach maximizes senescent cell clearance while allowing healthy cells to recover.
If senolytics can safely and effectively clear senescent cells in humans, they represent a genuine rejuvenation therapy — not just slowing aging, but partially reversing it at the cellular level.